Cargando…

The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines

BACKGROUND: General control nonderepressible 2 (GCN2) senses amino acid deprivation and activates activating transcription factor 4 (ATF4), which regulates many adaptive genes. We evaluated the impact of AST-0513, a novel GCN2 inhibitor, on the GCN2-ATF4 pathway. Additionally, we evaluated the antit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jeongjae, Keam, Bhumsuk, Kim, Soyeon, Heo, Jung-Nyoung, Joung, Eunkyo, Kim, Miso, Kim, Tae Min, Kim, Dong-Wan, Heo, Dae Seog
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694079/ https://www.ncbi.nlm.nih.gov/pubmed/36436443 http://dx.doi.org/10.1016/j.tranon.2022.101592

Ejemplares similares

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
por: Kim, Ryul, et al.
Publicado: (2016)

Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis
por: Park, Ha-Ram, et al.
Publicado: (2022)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
por: Ock, Chan-Young, et al.
Publicado: (2016)

Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
por: Kim, Miso, et al.
Publicado: (2023)

Generalization and representativeness of phase III immune checkpoint blockade trials in non‐small cell lung cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
por: Ock, Chan-Young, et al.
Publicado: (2017)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
por: Choi, Ji Young, et al.
Publicado: (2019)

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
por: Lee, Chaelin, et al.
Publicado: (2022)

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
por: Oh, So Yeon, et al.
Publicado: (2021)

Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation
por: Ock, Chan-Young, et al.
Publicado: (2016)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma
por: Kim, Ryul, et al.
Publicado: (2016)

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study
por: Kim, Ryul, et al.
Publicado: (2016)

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Heo, Ja Yoon, et al.
Publicado: (2019)

A Phase II Study of Genexol‐PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Keam, Bhumsuk, et al.
Publicado: (2019)

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
por: Kim, Miso, et al.
Publicado: (2018)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
por: Ock, Chan-Young, et al.
Publicado: (2019)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
por: Nam, Chang Hyun, et al.
Publicado: (2021)

Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
por: Yoo, Shin Hye, et al.
Publicado: (2019)

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
por: Kim, Hyungjin, et al.
Publicado: (2017)

Squamous cell carcinoma of head and neck: what internists should know
por: Jung, Kyungsuk, et al.
Publicado: (2020)

Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance
por: Suh, Koung Jin, et al.
Publicado: (2019)

Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
por: Heo, Ja Yoon, et al.
Publicado: (2021)

The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer
por: Lee, June-Koo, et al.
Publicado: (2015)

Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute
por: Choi, Younak, et al.
Publicado: (2015)

Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
por: Kim, Miso, et al.
Publicado: (2015)

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
por: Jo, Jaemin, et al.
Publicado: (2018)

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2017)

Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer
por: Kim, Sehui, et al.
Publicado: (2019)

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
por: Kim, Miso, et al.
Publicado: (2021)

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
por: Cho, Kyoung Min, et al.
Publicado: (2019)

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor
por: Park, Sehhoon, et al.
Publicado: (2018)

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Kim, Hyun Jee, et al.
Publicado: (2018)

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations
por: Park, Sehhoon, et al.
Publicado: (2016)

Hospice-Palliative Medicine as a Model of Value-Based Healthcare
por: Heo, Dae Seog, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aj1immkg4iruvkrcrgirqp3tn0